Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1084/jem.20200653 http://scihub22266oqcxt.onion/10.1084/jem.20200653 32289152!7155807!32289152     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Exp+Med 2020 ; 217 (5): ä Nephropedia Template TP {{tp|p=32289152|t=2020. COVID-19 and emerging viral infections: The case for interferon lambda |pdf=|usr=}}{{32289152}} gab.com Text COVID-19 and emerging viral infections: The case for interferon lambda JO: J Exp Med http://www.kidney.de/pget.php?&tw=1&pmid=32289152 #FOAvip With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-lambda) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-lambda to prevent, limit, and treat these dangerous viral infections. Twit Text FOAVip COVID-19 and emerging viral infections: The case for interferon lambda ????J Exp Med http://www.kidney.de/pget.php?&tw=1&pmid=32289152 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32289152 #FOAvip English Wikipedia <ref>{{Cite pmid|32289152}}</ref> COVID-19 and emerging viral infections: The case for interferon lambda #MMPMID32289152 Prokunina-Olsson L; Alphonse N; Dickenson RE; Durbin JE; Glenn JS; Hartmann R; Kotenko SV; Lazear HM; O'Brien TR; Odendall C; Onabajo OO; Piontkivska H; Santer DM; Reich NC; Wack A; Zanoni I J Exp Med 2020[May]; 217 (5): ä PMID32289152show ga With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-lambda) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-lambda to prevent, limit, and treat these dangerous viral infections. |Betacoronavirus/*physiology[MESH] |COVID-19[MESH] |Coronavirus Infections/*metabolism[MESH] |Humans[MESH] |Interferons/*metabolism[MESH] |Pandemics[MESH] |Pneumonia, Viral/*metabolism[MESH] |SARS-CoV-2[MESH]COVID-19 and emerging viral infections: The case for interferon lambda(epmc).pdf DeepDyve Pubget Overpricing